What an FDA Warning Letter Tells Us About AI, Human Oversight, and Getting Validation Right
A warning letter the FDA issued in April 2026 to Purolea Cosmetics Lab in Livonia, Michigan reads like a textbook case of what happens when quality processes break down without qualified human oversight in place. Inspectors found insects, filth, and clutter in manufacturing areas. A docking bay door opened directly to the outside environment during production. Finished drug products were released without microbiological testing. Component suppliers were trusted without independent verification of their test results.
None of those failures required sophisticated technology to prevent. They required knowledgeable people applying standard practice in a disciplined way.
That is the lesson worth carrying into the conversation about AI in life sciences validation: the question is never whether AI is capable. It is whether the humans directing and reviewing its outputs actually know what they are looking at.
What the Warning Letter Really Shows
The Purolea case is not primarily a technology failure. It is a failure of qualified oversight. The firm had processes on paper. What it lacked was the domain expertise to recognize when those processes were not being followed, and what the regulatory consequences of that gap would look like.
This is precisely the failure mode that emerges when organizations treat compliance as a documentation exercise rather than a substantive quality practice. You can produce documents without understanding them. You can answer a checklist without understanding why each question exists. And when a regulator shows up, the gap between what is on paper and what is actually happening becomes very visible very quickly.
The parallel to AI adoption in validation is direct. AI can generate a URS or an IQ protocol quickly and at low cost. What it cannot do, on its own, is ensure that the output reflects the actual system, meets current regulatory expectations, and would hold up to examiner scrutiny. That requires a subject matter expert who understands both the document type and the regulatory context it lives in.
The warning letter is a reminder that expertise is not optional in regulated environments. It is the load-bearing element of the entire quality system.
Why Copilot and General-Purpose AI Are Good Starting Points but Not Good Enough
Most life sciences organizations that have begun exploring AI for validation documentation started with a general-purpose tool. Copilot is the most common entry point, because it requires no procurement and no IT project. It is already in the environment. Teams run experiments, generate some draft text, and get a feel for what the technology can do.
That experimentation is genuinely useful. It builds intuition about where AI adds value and where it produces outputs that require significant correction. It creates internal advocates. It surfaces the questions that need to be answered before any serious deployment.
But it also creates a structural problem that becomes clearer at scale.
General-purpose tools were not designed for GxP documentation. They do not carry institutional knowledge of regulatory frameworks. They do not maintain version history by intended use or system type. They do not flag when a generated output is inconsistent with 21 CFR Part 11 requirements or when a protocol scope does not match the system's actual functionality. And they hallucinate in ways that are particularly dangerous in a regulated context, producing plausible-sounding text that is factually incorrect, with no mechanism in the workflow to catch it before a qualified reviewer signs off.
The hallucination problem alone makes direct deployment of general-purpose AI for GxP documentation a serious risk at production scale. A hallucinated test requirement in an OQ protocol that passes initial review because it sounds correct is not a theoretical concern. It is a predictable outcome of deploying a general-purpose tool without structured quality checks on the output.
The Purolea warning letter names the same failure in analog form: releasing products without the testing required to confirm they were safe. The mechanism is different. The structural problem is identical. You cannot skip the verification step and call the output compliant.
The Catch-22 That Stops Most Teams From Moving Forward
The AI adoption conversation in validation has a well-known sticking point. Demonstrating ROI requires real project data. Generating real project data requires running a real project. Running a real project requires budget. Budget requires demonstrated ROI.
That circular logic is not a failure of imagination on the part of validation leaders. It is a reasonable response to genuine uncertainty in an environment where the cost of getting it wrong is high.
Teams that try to break the cycle independently usually end up on one of two paths. They experiment with Copilot and discover that the output requires more correction than expected, the governance overhead is significant, and the ROI case is harder to make cleanly because implementation cost is now entangled with the result. Or they pursue a direct API integration with an LLM provider, which introduces data privacy questions, prompt engineering overhead, and the shadow AI risk of parallel team-level experiments running outside any governance structure.
Both paths generate noise instead of signal. The evidence question does not get answered. The cycle continues.
Why AI Validation as a Service Is the Right Way to Start
Validation as a Service solves the Catch-22 by removing the infrastructure problem from the equation.
Rather than requiring an organization to build AI capability internally, hire specialized talent, develop prompt engineering expertise, and implement hallucination detection before generating a single document, VaaS delivers the output directly. You submit the system documentation you already have. CIMCON's validation experts, using the AIValidator platform, return draft URS, IQ, OQ, and RTM documents within one to two weeks at a fixed cost.